Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Operations: 2010-2025

Historic Cash from Operations for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Sep 2025 value amounting to $32.4 million.

  • Catalyst Pharmaceuticals' Cash from Operations fell 55.49% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.7 million, marking a year-over-year increase of 4.49%. This contributed to the annual value of $239.8 million for FY2024, which is 67.00% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Cash from Operations of $32.4 million as of Q3 2025, which was down 54.50% from $71.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Cash from Operations ranged from a high of $72.9 million in Q3 2024 and a low of $3.8 million during Q1 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Cash from Operations value was $55.6 million (recorded in 2023), while the average stood at $49.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 164.50% in 2024, then crashed by 55.49% in 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Cash from Operations (Quarterly) stood at $19.2 million in 2021, then skyrocketed by 109.00% to $40.1 million in 2022, then soared by 38.85% to $55.6 million in 2023, then grew by 27.37% to $70.9 million in 2024, then plummeted by 55.49% to $32.4 million in 2025.
  • Its last three reported values are $32.4 million in Q3 2025, $71.3 million for Q2 2025, and $60.0 million during Q1 2025.